Loading…
← CockpitCompetitor Analysis › 9995.HK RemeGen Co. Ltd. Class HOpen in the cockpit ↗

RemeGen Co. Ltd. Class H9995.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biotech developing biologic drugs for autoimmune diseases and cancer, including telitacicept.

≈ A Chinese autoimmune/oncology biologics biotechMomentum weak 33
Mkt cap
$6.07B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$17.3M
20-day average traded
Fwd P/E
6.3×
forward earnings
ROIC−WACC
+108.0 pp
WACC 9.6%
Hurdle
-65 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$60.85
1D-3.2%
1W-13.0%
1M-5.7%
3M-21.9%
6M-28.3%
YTD-15.5%
1Y-27.7%
ATR %5.8%
52w lowhigh50.6% off high

What RemeGen does

Chinese biotech developing biologic drugs for autoimmune diseases and cancer, including telitacicept.

Earns from sales of its two lead drugs in China, mostly to hospitals, and from licensing: overseas rights to disitamab vedotin were licensed to Seagen, now part of Pfizer, bringing upfront and milestone payments. These are the Hong Kong-listed H shares.

In one line: A Chinese autoimmune/oncology biologics biotech.

Products and services

  • Telitacicept (autoimmune biologic)
  • Disitamab vedotin (ADC oncology drug)
  • Other biologics pipeline

Customers

  • Hospitals treating autoimmune disease and cancer
  • Global licensing partners

Where it sits in the supply chain

  • Healthcare
  • Biopharma
  • Autoimmune & oncology biologic drug…

What could go right

  • Telitacicept sales growth/global licensing
  • New indication approvals

What could go wrong

  • Still loss-making/cash-burn biotech
  • Clinical-trial/pipeline failure risk

Moat: narrow (IP / patents, process know-how). Proprietary biologics platform with first-in-class/best-in-class autoimmune and ADC assets.

Headquarters: Yantai, China · Founded: 2008 · Employees: 3,048

Named competitors

RemeGen at a glance

Size RemeGen (9995.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $6.07B, the 222nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$60.85 on 18 Nov 2026.

Performance Over six months the shares fell 28.3%, against -0.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 292.8% over the last twelve months (peer median +11.6%); the operating margin is 61.1% (peer median 17.2%).

Valuation It trades at 6.3× forward earnings against a peer median of 24.4× (cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +58%, so the hurdle is -65 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 108.0 points above its cost of capital (9.6% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 999995.HK 71
Six months, rebased to 100: RemeGen against the median of its 20 peers (local-currency closes).

RemeGen financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$9.46BHK$3.52BHK$1.85BHK$1.19BHK$893M
Revenue growth—+90%+56%+33%—
Gross profitHK$8.94BHK$2.87BHK$1.35BHK$715MHK$362M
EBITDAn/aHK$481M-HK$1.45B-HK$1.48B-HK$1.19B
Net incomeHK$7.45BHK$770M-HK$1.59B-HK$1.67B-HK$1.16B
Free cash flowHK$4.44BHK$385Mn/a-HK$2.53B-HK$2.35B
Capital expenditureHK$153MHK$216Mn/aHK$851MHK$881M
Total debtHK$342MHK$2.45BHK$2.84BHK$1.39BHK$185M

Quarterly statements and history in the cockpit →

RemeGen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%MIRMSUPNLGNDBIOCONABBOTINDIABLTEGLAND0126Z0ORKA000999603087ALKEM000963688578MANE9926BANB68219995.HK6-month return →1-month return →
Up and to the right = strong over both horizons. RemeGen is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%20×40×60×SUPNLGNDBIOCONABBOTINDIAGLANDAPTX000999ALKEM45066885789995.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. RemeGen is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%SUPNLGNDABBOTINDIA6885789995.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. RemeGen is the large dot.

RemeGen competitors and peer comparison

Head to head with its named competitors (9995.HK vs 1801.HK vs 9926.HK vs 6990.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
RemeGen 9995.HK$6.07B-28%+293%61%6.3×-6.8%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Akeso 9926.HK$7.01B-48%+42%-25%n/an/a
Sichuan Kelun-Biotech Biopharmaceutical 6990.HK$13.0B-1%+44%-38%1,176.1×55.3%

How RemeGen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

RemeGen against its 20 peers (data as of 18 Nov 2026)
Measure9995.HKPeer medianRank in peer set
1-month return-5.7%-0.3%7th lowest of 21
6-month return-28.3%-0.4%4th lowest of 20
Distance from 52-week high-50.6%-21.1%4th lowest of 21
Revenue growth (TTM)+292.8%+11.6%highest of 17
Operating margin61.1%17.2%highest of 18
Forward P/E6.3×24.4×cheapest of 16
Growth the price implies (Req g, 7 yrs)-6.8%3.9%2nd least demanding of 11
Growth delivered (Del g)+57.9%+10.3%2nd highest of 11
Hurdle (Req g minus delivered)-64.7 pp-4.8 pp2nd least demanding of 11
ROIC minus cost of capital+108.0 pp+1.8 pphighest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a

Questions

Who are RemeGen's main competitors?
Named competitors: Innovent Biologics (1801.HK), Akeso (9926.HK), Sichuan Kelun-Biotech (6990.HK), UCB (private or unlisted). The cockpit's measured peer set (industry) also includes Mirum Pharmaceuticals (MIRM), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Biocon (BIOCON.NS), Abbott India (ABBOTINDIA.NS), Belite Bio, Inc. ADR (BLTE).
Is RemeGen expensive compared with its peers?
On forward p/e it trades at 6.3× against a peer median of 24.4×, cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +58%, so the hurdle is -65 pp: the price already allows for a slowdown.
How has RemeGen stock performed?
Over six months to 18 Nov 2026 the shares returned -28.3% against -0.4% for the median peer; over one year -27.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.